STOCK TITAN

SomaLogic, Inc. - SLGC STOCK NEWS

Welcome to our dedicated page for SomaLogic news (Ticker: SLGC), a resource for investors and traders seeking the latest updates and insights on SomaLogic stock.

SomaLogic, Inc. (Nasdaq: SLGC) is a pioneering company in the field of proteomics, dedicated to transforming healthcare through innovative solutions for detecting and diagnosing diseases. Founded in 2000, SomaLogic leverages decades of aptamer research to offer cutting-edge proteomic technologies that surpass current industry challenges. The company's proprietary platform facilitates the measurement of 11,000 proteins from a single 55-microliter plasma or serum sample, covering a substantial portion of the human proteome.

SomaLogic's mission is to revolutionize life sciences and clinical diagnostics by discovering, developing, and commercializing revolutionary research tools and diagnostic products. Over the past 20 years, the company has worked closely with pharmaceutical firms, academic institutions, and contract research organizations to fuel advancements in drug discovery, disease understanding, and treatment development, particularly in areas such as oncology, diabetes, cardiovascular, liver, and metabolic diseases.

In recent developments, SomaLogic has been at the center of a proposed merger with Standard BioTools, Inc. (Nasdaq: LAB). This transaction has sparked significant debate among stakeholders, with some expressing opposition and filing lawsuits, while others, including SomaLogic's board, advocate for the merger, citing potential value maximization benefits. The final outcome will be determined following stockholder votes and customary closing conditions, with the merger expected to finalize in early 2024.

For more information about SomaLogic, visit somalogic.com or contact their team at information@somalogic.com or 303-625-9000.

Rhea-AI Summary

SomaLogic (NASDAQ: SLGC) has expanded its SomaLogic™ Certified Site program through a partnership with Group 42 Healthcare (G42) in the UAE and KSA. G42 will exclusively utilize SomaLogic's high-plex proteomics technology, becoming the first certified site in the Middle East. This collaboration aims to enhance personalized and preventive healthcare in the region, leveraging SomaLogic's industry-leading proteome coverage and sensitivity. G42 will establish a lab in Abu Dhabi to conduct protein measurements using SomaScan Assay kits, further enhancing regional healthcare delivery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
none
-
Rhea-AI Summary

SomaLogic, Inc. announced preliminary, unaudited revenue for 2022 is expected to reach $93-98 million, representing approximately 20% year-over-year growth. The company signed a significant agreement with G42 Healthcare to serve as its exclusive proteomics provider in the MENA region. Additionally, SomaLogic extended its contract with Novartis, ensuring continued collaboration through 2033. The company is also optimizing its organization to focus on long-term growth opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.73%
Tags
none
-
Rhea-AI Summary

SomaLogic, a leader in proteomics technology, is set to participate in the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 a.m. Pacific Time. The conference will allow interested parties to access a live audio webcast of the presentation via the company's website. SomaLogic focuses on providing actionable health-management information through the measurement of proteins, helping individuals optimize their health over time. For further details, visit SomaLogic's investor page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences
Rhea-AI Summary

SomaLogic has announced that FonesLife Corporation will be the first SomaLogic™ Certified Site in Japan, enabling the use of the 7,000-plex SomaScan® Assay in their labs. This partnership will enhance FonesLife's capabilities in the Asia-Pacific region and expedite research by providing local access to SomaScan data. The Certified Site program aims to expand SomaLogic's reach in life sciences and clinical research globally. As of now, SomaLogic has processed over 550,000 samples and continues to grow its network of certified sites across various regions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.31%
Tags
none
-
Rhea-AI Summary

SomaLogic, a leader in proteomics technology, has launched its global SomaLogic™ Certified Site program, enabling institutions to run the 7,000-plex SomaScan® Assay in their labs. This program allows certified labs to conduct research and generate revenue as service providers. The SomaScan Assay measures over 7,000 proteins per sample and provides various assay kits for different sample types. Certified sites, including those at the NIH and Washington University, receive extensive support, training, and equipment servicing. New sites are expected to be added in 2023 across multiple regions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
Rhea-AI Summary

SomaLogic is conducting a randomized controlled study involving 248 physicians to assess whether SomaSignal tests improve risk stratification for cardiovascular disease. The research, led by UCSF, aims to determine if these tests enhance the prescription of drugs like SGLT2 inhibitors and GLP-1 receptor agonists for high-risk patients. Previous findings indicated difficulties with traditional risk factors. A positive outcome could significantly influence clinical practice and patient treatment alignment with medical guidelines. The complete study will be published in a peer-reviewed journal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
none
Rhea-AI Summary

SomaLogic (NASDAQ: SLGC) reported a strong third quarter 2022, with revenues reaching $41.7 million, up 108.6% year-over-year. Core life sciences revenue was $20.5 million, marking a 45.4% sequential growth. The company raised its full-year revenue guidance to $93 to $98 million, aided by $21.2 million in licensing royalties. Despite operational expenses growing, SomaLogic is on track to reduce costs by $75 million through 2023, maintaining a robust cash position of $566.3 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
-
Rhea-AI Summary

SomaLogic announced a partnership with Singapore-based Molecular Genomics, launching the 7,000-plex SomaScan Assay in Asia. This collaboration aims to enhance multi-omics services in Southeast Asia, combining SomaLogic’s proteomics platform with genomics analysis. The partnership aligns with the growing demand for clinical research and life sciences in the region. SomaLogic's SomaScan can perform approximately 7,000 protein measurements from a single blood sample and has processed over 550,000 samples to date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
none
-
Rhea-AI Summary

SomaLogic (NASDAQ: SLGC) announced its participation in the upcoming American Heart Association Scientific Sessions, where it will lead five discussions highlighting the role of proteomics in cardiovascular health. Key studies will explore protein signatures related to cardiometabolic health, stroke, and COVID-19 outcomes. Sessions are scheduled from November 5-7, 2022, in Chicago. This event aims to showcase the potential of proteomic technologies in transforming patient care through precise health insights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.15%
Tags
none
Rhea-AI Summary

The National Institutes of Health recently conducted a technical assessment of the 7K SomaScan® Platform, revealing its strengths in proteome coverage, sensitivity, and low variability. The study evaluated 2,050 plasma samples across 102 subjects, confirming the platform's capability in biomarker discovery and diagnostic applications. SomaLogic's Chief Medical Officer emphasized the platform's power in measuring protein concentrations, stating it significantly outperformed traditional assays. This independent validation supports SomaLogic's ongoing improvement and growth in proteomic research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none

FAQ

What is the market cap of SomaLogic (SLGC)?

The market cap of SomaLogic (SLGC) is approximately 396.2M.

What does SomaLogic, Inc. specialize in?

SomaLogic specializes in proteomics technology, offering advanced solutions for detecting and diagnosing diseases by measuring proteins in the human body.

When was SomaLogic founded?

SomaLogic was founded in 2000.

What recent important event has SomaLogic been involved in?

SomaLogic has been involved in a proposed merger with Standard BioTools, Inc., which has led to significant discussions and legal actions among stakeholders.

What applications does SomaLogic's technology have?

SomaLogic's technology is used in drug discovery, disease research, and treatment development, benefiting areas such as oncology, diabetes, and cardiovascular diseases.

How many proteins can SomaLogic measure with a single sample?

SomaLogic can measure 11,000 proteins from a single 55-microliter plasma or serum sample.

Who can benefit from SomaLogic's proteomics technology?

Pharmaceutical companies, academic institutions, and contract research organizations benefit significantly from SomaLogic's advanced protein detection and analysis capabilities.

What is the mission of SomaLogic?

SomaLogic's mission is to transform healthcare by developing and commercializing revolutionary research tools and diagnostic products in the life sciences.

How can I learn more about SomaLogic?

You can learn more about SomaLogic by visiting their website at somalogic.com or contacting them at information@somalogic.com or 303-625-9000.

What is the status of the merger between SomaLogic and Standard BioTools?

The merger has been approved by SomaLogic stockholders and is expected to close in early 2024, subject to final conditions.

Who are the key executives at SomaLogic?

Key executives include Dr. Larry Gold, the founder, and Dr. Jason Cleveland, the Chief Technology Officer.

SomaLogic, Inc.

Nasdaq:SLGC

SLGC Rankings

SLGC Stock Data

396.23M
175.53M
2.16%
61.71%
3.79%
Health Information Services
Healthcare
Link
United States
Boulder